Page 1 | Search Results | Blood Advances | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Ibrutinib for therapy of steroid-refractory chronic graft vs. host disease: A multicenter real-world analysis

Blood Adv bloodadvances.2024014374.

https://doi.org/10.1182/bloodadvances.2024014374

Published: 2024

Includes: Supplemental data

Journal Articles

Active infection at the time of CD34 + selected stem cell boost is associated with treatment failure and poor overall survival

Blood Adv (2024) 8 (17): 4729–4737.

https://doi.org/10.1182/bloodadvances.2023012418

Published: 2024

Includes: Supplemental data

Journal Articles

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML

Blood Adv (2024) 8 (4): 978–990.

https://doi.org/10.1182/bloodadvances.2023012120

Published: 2024

Includes: Supplemental data

Journal Articles

Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse

Roman M. Shapiro, Haesook T. Kim, Michela Ansuinelli, Indira Guleria, Corey S. Cutler, John Koreth, Mahasweta Gooptu, Joseph H. Antin, Amar Kelkar, Jerome Ritz, Catherine J. Wu, Robert J. Soiffer, Vincent T. Ho, Sarah Nikiforow, Rizwan Romee

Blood Adv (2023) 7 (15): 4080–4088.

https://doi.org/10.1182/bloodadvances.2023009657

Published: 2023

Includes: Supplemental data

Journal Articles

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis

Mahasweta Gooptu, Haesook T. Kim, Eric Jacobsen, David C. Fisher, Ann LaCasce, Vincent T. Ho, Corey S. Cutler, John Koreth, Robert J. Soiffer, Joseph H. Antin, Nancy Berliner, Sarah Nikiforow

Blood Adv (2023) 7 (11): 2309–2316.

https://doi.org/10.1182/bloodadvances.2022007012

Published: 2023

Includes: Supplemental data

Journal Articles

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease

Jennifer S. Whangbo, Sarah Nikiforow, Haesook T. Kim, Jonathan Wahl, Carol G. Reynolds, Sharmila C. Rai, Soomin Kim, Andrew Burden, Ana C. Alho, João F. Lacerda, Edwin P. Alyea, III, Corey S. Cutler, Vincent T. Ho, Joseph H. Antin, Robert J. Soiffer, Jerome Ritz, John Koreth

Blood Adv (2022) 6 (21): 5786–5796.

https://doi.org/10.1182/bloodadvances.2021006625

Published: 2022

Includes: Supplemental data

Journal Articles

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

Blood Adv (2021) 5 (24): 5536–5545.

https://doi.org/10.1182/bloodadvances.2021005566

Published: 2021

Includes: Supplemental data

Journal Articles

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium

Zachariah DeFilipp, Amin M. Alousi, Joseph A. Pidala, Paul A. Carpenter, Lynn E. Onstad, Sally Arai, Mukta Arora, Corey S. Cutler, Mary E. D. Flowers, Carrie L. Kitko, George L. Chen, Stephanie J. Lee, Betty K. Hamilton

Blood Adv (2021) 5 (20): 4278–4284.

https://doi.org/10.1182/bloodadvances.2021004941

Published: 2021

Includes: Supplemental data

Journal Articles

Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

Blood Adv (2021) 5 (4): 975–983.

https://doi.org/10.1182/bloodadvances.2020003654

Published: 2021

Journal Articles

Survival following allogeneic transplant in patients with myelofibrosis

Krisstina Gowin, Karen Ballen, Kwang Woo Ahn, Zhen-Huan Hu, Haris Ali, Murat O. Arcasoy, Rebecca Devlin, Maria Coakley, Aaron T. Gerds, Michael Green, Vikas Gupta, Gabriela Hobbs, Tania Jain, Malathi Kandarpa, Rami Komrokji, Andrew T. Kuykendall, Kierstin Luber, Lucia Masarova, Laura C. Michaelis, Sarah Patches, Ashley C. Pariser, Raajit Rampal, Brady Stein, Moshe Talpaz, Srdan Verstovsek, Martha Wadleigh, Vaibhav Agrawal, Mahmoud Aljurf, Miguel Angel Diaz, Belinda R. Avalos, Ulrike Bacher, Asad Bashey, Amer M. Beitinjaneh, Jan Cerny, Saurabh Chhabra, Edward Copelan, Corey S. Cutler, Zachariah DeFilipp, Shahinaz M. Gadalla, Siddhartha Ganguly, Michael R. Grunwald, Shahrukh K. Hashmi, Mohamed A. Kharfan-Dabaja, Tamila Kindwall-Keller, Nicolaus Kröger, Hillard M. Lazarus, Jane L. Liesveld, Mark R. Litzow, David I. Marks, Sunita Nathan, Taiga Nishihori, Richard F. Olsson, Attaphol Pawarode, Jacob M. Rowe, Bipin N. Savani, Mary Lynn Savoie, Sachiko Seo, Melhem Solh, Roni Tamari, Leo F. Verdonck, Jean A. Yared, Edwin Alyea, Uday Popat, Ronald Sobecks, Bart L. Scott, Ryotaro Nakamura, Ruben Mesa, Wael Saber

Blood Adv (2020) 4 (9): 1965–1973.

https://doi.org/10.1182/bloodadvances.2019001084

Published: 2020

Includes: Supplemental data

Journal Articles

BK virus–specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation

Blood Adv (2020) 4 (9): 1881–1893.

https://doi.org/10.1182/bloodadvances.2019001120

Published: 2020

Includes: Supplemental data

Journal Articles

Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children

Blood Adv (2019) 3 (17): 2550–2561.

https://doi.org/10.1182/bloodadvances.2019000631

Published: 2019

Includes: Supplemental data

Journal Articles

Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation

Blood Adv (2019) 3 (14): 2199–2204.

https://doi.org/10.1182/bloodadvances.2019000445

Published: 2019

Includes: Supplemental data

Journal Articles

Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease

Blood Adv (2019) 3 (7): 969–979.

https://doi.org/10.1182/bloodadvances.2018029124

Published: 2019

Includes: Supplemental data

Journal Articles

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease

Jennifer S. Whangbo, Haesook T. Kim, Sarah Nikiforow, John Koreth, Ana C. Alho, Bryn Falahee, Soomin Kim, Katharine Dusenbury, Marie J. Fields, Carol G. Reynolds, Edwin P. Alyea, III, Philippe Armand, Corey S. Cutler, Vincent T. Ho, Joseph H. Antin, Robert J. Soiffer, Jerome Ritz

Blood Adv (2019) 3 (7): 984–994.

https://doi.org/10.1182/bloodadvances.2018027474

Published: 2019

Includes: Supplemental data

Journal Articles

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802

Blood Adv (2018) 2 (15): 1882–1888.

https://doi.org/10.1182/bloodadvances.2018017343

Published: 2018

Includes: Supplemental data

Journal Articles

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants

Blood Adv (2018) 2 (9): 1022–1031.

https://doi.org/10.1182/bloodadvances.2017013052

Published: 2018

Journal Articles

Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease

Zachariah DeFilipp, Rosalynn M. Nazarian, Areej El-Jawahri, Shuli Li, Jami Brown, Candice Del Rio, Melissa Smith, Betsy Valles, Karen K. Ballen, Steven L. McAfee, Jacalyn Rosenblatt, Joseph H. Antin, Corey S. Cutler, Yi-Bin Chen

Blood Adv (2017) 1 (22): 1919–1922.

https://doi.org/10.1182/bloodadvances.2017011239

Published: 2017

NARROW

Ibrutinib for therapy of steroid-refractory chronic graft vs. host disease: A multicenter real-world analysis

Active infection at the time of CD34 + selected stem cell boost is associated with treatment failure and poor overall survival

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML

Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium

Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

Survival following allogeneic transplant in patients with myelofibrosis

BK virus–specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation

Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children

Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation

Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants

Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only